NASDAQ:JNP - Columbia Laboratories Stock Price, Price Target & More

$8.65 -0.40 (-4.42 %)
(As of 04/23/2018 04:00 PM ET)
Previous Close$9.05
Today's Range$8.65 - $9.00
52-Week Range$3.90 - $13.25
Volume73,815 shs
Average Volume96,633 shs
Market Capitalization$99.33 million
P/E Ratio-57.67
Dividend YieldN/A
Beta0.46

About Columbia Laboratories (NASDAQ:JNP)

Columbia Laboratories logoJuniper Pharmaceuticals, Inc., a women's health therapeutic company, focuses on developing therapeutics that address unmet medical needs in women's health. The company develops its products using its drug delivery technologies, including bioadhesive delivery system, a polymer designed to adhere to epithelial surfaces or mucosa for sustained and controlled delivery of active drug product; and a novel intra-vaginal ring (IVR) technology. It markets CRINONE, a progesterone bioadhesive vaginal gel for progesterone supplementation or replacement as part of an assisted reproductive technology treatment for infertile women with progesterone deficiency. The company is also developing COL-1077, a lidocaine bioadhesive gel, which is in Phase 2b clinical trial for use as an acute use anesthetic for pain from minimally invasive gynecological procedures. Its products in preclinical development include JNP-0101, an oxybutynin IVR to treat overactive bladder in women; JNP-0201, a product candidate with natural progesterone and natural estradiol for used in hormone replacement therapy in menopausal women; and JNP-0301, a natural progesterone IVR used for the prevention of preterm birth. In addition, Juniper Pharmaceuticals, Inc. provides pharmaceutical development, clinical trial manufacturing, analytical, and consulting services. The company was formerly known as Columbia Laboratories, Inc. and changed its name to Juniper Pharmaceuticals, Inc. in April 2015. Juniper Pharmaceuticals, Inc. was founded in 1986 and is based in Boston, Massachusetts.

Receive JNP News and Ratings via Email

Sign-up to receive the latest news and ratings for JNP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:JNP
CUSIPN/A
Phone617-639-1500

Debt

Debt-to-Equity Ratio0.08%
Current Ratio2.20%
Quick Ratio1.81%

Price-To-Earnings

Trailing P/E Ratio-57.67
Forward P/E Ratio2.47
P/E GrowthN/A

Sales & Book Value

Annual Sales$49.98 million
Price / Sales1.90
Cash Flow$0.0167 per share
Price / Cash516.52
Book Value$3.83 per share
Price / Book2.26

Profitability

EPS (Most Recent Fiscal Year)($0.15)
Net Income$-2,060,000.00
Net Margins-4.12%
Return on Equity-3.91%
Return on Assets-2.62%

Miscellaneous

Employees155
Outstanding Shares10,980,000

How to Become a New Pot Stock Millionaire

Columbia Laboratories (NASDAQ:JNP) Frequently Asked Questions

What is Columbia Laboratories' stock symbol?

Columbia Laboratories trades on the NASDAQ under the ticker symbol "JNP."

How were Columbia Laboratories' earnings last quarter?

Columbia Laboratories, Inc. (NASDAQ:JNP) posted its earnings results on Thursday, March, 8th. The specialty pharmaceutical company reported $0.11 EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.22. The specialty pharmaceutical company earned $11.79 million during the quarter, compared to analysts' expectations of $16 million. Columbia Laboratories had a negative net margin of 4.12% and a negative return on equity of 3.91%. View Columbia Laboratories' Earnings History.

What price target have analysts set for JNP?

3 brokers have issued 1 year price objectives for Columbia Laboratories' shares. Their forecasts range from $24.00 to $34.00. On average, they anticipate Columbia Laboratories' share price to reach $29.00 in the next twelve months. View Analyst Ratings for Columbia Laboratories.

Who are some of Columbia Laboratories' key competitors?

Who are Columbia Laboratories' key executives?

Columbia Laboratories' management team includes the folowing people:
  • Ms. Alicia Secor, Chief Exec. Officer, Pres and Director (Age 55)
  • Dr. Nikin Patel Ph.D., MRPharmS, COO & Director (Age 45)
  • Mr. Jeffrey E. Young, CFO, Sr. VP of Fin., Treasurer & Sec. (Age 45)
  • Dr. Shen Luk BSc, Ph.D., Chief Scientific Officer
  • Dr. Claire Madden-Smith BSc, Ph.D., Sr. VP of Juniper Pharma Services

Has Columbia Laboratories been receiving favorable news coverage?

Media coverage about JNP stock has trended somewhat positive recently, Accern Sentiment reports. Accern identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Columbia Laboratories earned a media sentiment score of 0.12 on Accern's scale. They also gave news stories about the specialty pharmaceutical company an impact score of 45.99 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

How do I buy shares of Columbia Laboratories?

Shares of JNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Columbia Laboratories' stock price today?

One share of JNP stock can currently be purchased for approximately $8.65.

How big of a company is Columbia Laboratories?

Columbia Laboratories has a market capitalization of $99.33 million and generates $49.98 million in revenue each year. The specialty pharmaceutical company earns $-2,060,000.00 in net income (profit) each year or ($0.15) on an earnings per share basis. Columbia Laboratories employs 155 workers across the globe.

How can I contact Columbia Laboratories?

Columbia Laboratories' mailing address is 33 Arch Street, Boston MA, 02110. The specialty pharmaceutical company can be reached via phone at 617-639-1500 or via email at [email protected]


MarketBeat Community Rating for Columbia Laboratories (JNP)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  140 (Vote Outperform)
Underperform Votes:  159 (Vote Underperform)
Total Votes:  299
MarketBeat's community ratings are surveys of what our community members think about Columbia Laboratories and other stocks. Vote "Outperform" if you believe JNP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JNP will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Columbia Laboratories (NASDAQ:JNP) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Columbia Laboratories in the last 12 months. Their average twelve-month price target is $29.00, suggesting that the stock has a possible upside of 235.26%. The high price target for JNP is $34.00 and the low price target for JNP is $24.00. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.672.67
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $29.00$29.00$23.00$23.00
Price Target Upside: 235.26% upside211.83% upside374.23% upside346.60% upside

Columbia Laboratories (NASDAQ:JNP) Consensus Price Target History

Price Target History for Columbia Laboratories (NASDAQ:JNP)

Columbia Laboratories (NASDAQ:JNP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/9/2018Roth CapitalBoost Price TargetBuy$12.00 -> $24.00LowView Rating Details
11/6/2017HC WainwrightReiterated RatingNeutralN/AView Rating Details
7/14/2017BMO Capital MarketsUpgradeMarket Perform -> Outperform$31.00 -> $34.00LowView Rating Details
8/18/2016Northland SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 4/23/2016 forward)

Earnings

Columbia Laboratories (NASDAQ:JNP) Earnings History and Estimates Chart

Earnings by Quarter for Columbia Laboratories (NASDAQ:JNP)

Columbia Laboratories (NASDAQ:JNP) Earnings Estimates

Current Year EPS Consensus Estimate: $3.5 EPS
Next Year EPS Consensus Estimate: $1.32 EPS

Columbia Laboratories (NASDAQ JNP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/8/2018Q4 2017($0.11)$0.1070$16.00 million$11.79 millionViewListenView Earnings Details
11/2/2017Q3 2017($0.17)($0.08)$12.55 million$12.99 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.13)($0.03)$11.84 million$13.96 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.09)($0.13)$11.27 million$11.25 millionViewListenView Earnings Details
3/7/2017Q4 2016$0.45$0.88$15.33 million$20.93 millionViewListenView Earnings Details
11/15/2016Q3 2016($0.15)$0.02$10.58 million$11.56 millionViewN/AView Earnings Details
8/4/2016Q216($0.08)($0.16)$9.49 million$11.89 millionViewN/AView Earnings Details
5/4/2016Q116($0.08)$0.03$9.13 million$12.10 millionViewN/AView Earnings Details
3/10/2016Q415($0.02)($0.19)$7.89 million$7.60 millionViewN/AView Earnings Details
11/10/2015Q315($0.05)$0.09$7.10 million$11.50 millionViewN/AView Earnings Details
8/4/2015Q215($0.02)($0.03)$8.35 million$10.20 millionViewN/AView Earnings Details
5/6/2015Q115$0.04$0.07$7.80 million$8.30 millionViewN/AView Earnings Details
3/18/2015Q414$0.07($0.05)$7.93 million$7.30 millionViewN/AView Earnings Details
10/28/2014Q314$0.12$0.34$9.74 million$11.50 millionViewN/AView Earnings Details
7/31/2014Q2$0.11$0.01$6.86 millionViewN/AView Earnings Details
4/29/2014Q1 2014($0.01)$7.25 millionViewN/AView Earnings Details
3/5/2014Q413$0.08$7.10 million$7.80 millionViewN/AView Earnings Details
11/7/2013Q313$0.16$0.20$6.75 million$7.10 millionViewN/AView Earnings Details
8/7/2013Q2 2013$0.02$0.03$6.50 million$7.02 millionViewN/AView Earnings Details
5/9/2013Q1 2013$0.03$0.01$6.50 million$6.30 millionViewN/AView Earnings Details
3/14/2013Q4 2012$0.02$0.03$7.60 million$6.10 millionViewN/AView Earnings Details
11/8/2012Q3 2012$0.08$0.08ViewN/AView Earnings Details
8/8/2012Q2 2012$0.08$0.16ViewN/AView Earnings Details
5/4/2012Q1 2012($0.74)ViewN/AView Earnings Details
3/8/2012Q4 2011($0.08)($0.10)ViewN/AView Earnings Details
11/3/2011Q3 2011$0.22ViewN/AView Earnings Details
8/4/2011Q2 2011$0.08$0.83ViewN/AView Earnings Details
5/5/2011Q1 2011$0.08$0.63ViewN/AView Earnings Details
3/10/2011Q4 2010($0.24)$0.40ViewN/AView Earnings Details
11/4/2010Q3 2010($0.48)$0.07ViewN/AView Earnings Details
8/5/2010Q2 2010($0.72)($0.61)ViewN/AView Earnings Details
5/6/2010Q1 2010($0.72)($1.06)ViewN/AView Earnings Details
3/11/2010Q4 2009($0.64)($0.70)ViewN/AView Earnings Details
11/5/2009Q3 2009($0.64)($0.86)ViewN/AView Earnings Details
8/6/2009Q2 2009($0.80)($0.77)ViewN/AView Earnings Details
5/7/2009Q1 2009($0.56)($0.78)ViewN/AView Earnings Details
3/5/2009Q4 2008($0.56)($0.51)ViewN/AView Earnings Details
11/6/2008Q3 2008($0.80)($0.31)ViewN/AView Earnings Details
8/7/2008Q2 2008($0.80)($0.66)ViewN/AView Earnings Details
5/8/2008Q1 2008($0.66)ViewN/AView Earnings Details
3/11/2008Q4 2007($0.57)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Columbia Laboratories (NASDAQ:JNP) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Columbia Laboratories (NASDAQ JNP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.20%
Institutional Ownership Percentage: 40.07%
Insider Trading History for Columbia Laboratories (NASDAQ:JNP)
Institutional Ownership by Quarter for Columbia Laboratories (NASDAQ:JNP)

Columbia Laboratories (NASDAQ JNP) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/17/2017James A GeraghtyDirectorBuy2,000$4.82$9,640.0065,153View SEC Filing  
9/13/2016James A GeraghtyDirectorBuy2,000$5.97$11,940.0063,153View SEC Filing  
8/31/2016George ElstonCFOBuy1,000$5.50$5,500.001,000View SEC Filing  
8/26/2016C Ann MerrifieldDirectorBuy2,000$5.63$11,260.0015,193View SEC Filing  
8/25/2016Alicia SecorInsiderBuy5,000$5.75$28,750.005,000View SEC Filing  
8/23/2016James A GeraghtyDirectorBuy7,000$5.96$41,720.0058,216View SEC Filing  
12/4/2015C Ann MerrifieldDirectorBuy1,600$12.14$19,424.007,129View SEC Filing  
11/19/2015Nikin PatelCOOBuy5,000$11.82$59,100.00189,384View SEC Filing  
11/18/2015Frank Condella JrCEOBuy5,000$11.68$58,400.0079,720View SEC Filing  
8/14/2015C Ann MerrifieldDirectorBuy3,000$9.90$29,700.00View SEC Filing  
6/15/2015Frank M ArmstrongDirectorBuy1,255$7.95$9,977.25View SEC Filing  
6/9/2015Nikin PatelCOOBuy13,500$7.52$101,520.00View SEC Filing  
5/8/2015Frank Condella JrCEOBuy10,000$7.36$73,600.00View SEC Filing  
11/20/2014Donald H HunterDirectorBuy1,000$5.98$5,980.00View SEC Filing  
8/13/2014Frank Condella JrCEOBuy10,000$5.98$59,800.00View SEC Filing  
5/5/2014Frank Condella JrCEOBuy10,000$6.65$66,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Columbia Laboratories (NASDAQ JNP) News Headlines

Source:
DateHeadline
Columbia Laboratories (JNP) Upgraded to "Buy" by ValuEngineColumbia Laboratories (JNP) Upgraded to "Buy" by ValuEngine
www.americanbankingnews.com - April 8 at 11:48 AM
Juniper Pharmaceuticals (JNP) Upgraded by ValuEngine to HoldJuniper Pharmaceuticals (JNP) Upgraded by ValuEngine to Hold
www.americanbankingnews.com - April 3 at 11:08 AM
Juniper Pharmaceuticals (JNP) Rating Reiterated by HC WainwrightJuniper Pharmaceuticals (JNP) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - April 1 at 7:35 PM
Where Juniper Pharmaceuticals Inc’s (NASDAQ:JNP) Earnings Growth Stands Against Its IndustryWhere Juniper Pharmaceuticals Inc’s (NASDAQ:JNP) Earnings Growth Stands Against Its Industry
finance.yahoo.com - March 28 at 5:19 PM
Juniper Pharmaceuticals (JNP) Downgraded by ValuEngineJuniper Pharmaceuticals (JNP) Downgraded by ValuEngine
www.americanbankingnews.com - March 28 at 11:55 AM
Juniper Pharma (JNP) Names Richard Messina to Board - StreetInsider.comJuniper Pharma (JNP) Names Richard Messina to Board - StreetInsider.com
www.streetinsider.com - March 23 at 8:22 AM
Juniper Pharmaceuticals Appoints Richard Messina to Board of ... - PR Newswire (press release)Juniper Pharmaceuticals Appoints Richard Messina to Board of ... - PR Newswire (press release)
www.prnewswire.com - March 22 at 8:27 AM
Juniper Pharmaceuticals Appoints Richard Messina to Board of DirectorsJuniper Pharmaceuticals Appoints Richard Messina to Board of Directors
finance.yahoo.com - March 21 at 5:37 PM
At $12, Is Juniper Pharmaceuticals Inc (NASDAQ:JNP) A Buy?At $12, Is Juniper Pharmaceuticals Inc (NASDAQ:JNP) A Buy?
finance.yahoo.com - March 20 at 5:33 PM
Edited Transcript of JNP earnings conference call or presentation 8-Mar-18 1:30pm GMTEdited Transcript of JNP earnings conference call or presentation 8-Mar-18 1:30pm GMT
finance.yahoo.com - March 18 at 8:54 AM
Analyzing Theravance Biopharma (TBPH) & Juniper Pharmaceuticals (JNP)Analyzing Theravance Biopharma (TBPH) & Juniper Pharmaceuticals (JNP)
www.americanbankingnews.com - March 16 at 7:50 AM
Juniper Pharmaceuticals (JNP) Upgraded at ValuEngineJuniper Pharmaceuticals (JNP) Upgraded at ValuEngine
www.americanbankingnews.com - March 16 at 12:16 AM
Juniper Pharmaceuticals (JNP) Upgraded to B- by TheStreetJuniper Pharmaceuticals (JNP) Upgraded to B- by TheStreet
www.americanbankingnews.com - March 14 at 7:20 AM
Comparing BioLife Solutions (BLFS) and Juniper Pharmaceuticals (JNP)Comparing BioLife Solutions (BLFS) and Juniper Pharmaceuticals (JNP)
www.americanbankingnews.com - March 13 at 11:54 AM
Juniper Pharmaceuticals (JNP) Upgraded to "Hold" by ValuEngineJuniper Pharmaceuticals (JNP) Upgraded to "Hold" by ValuEngine
www.americanbankingnews.com - March 10 at 7:42 PM
Juniper Pharmaceuticals (JNP) Price Target Raised to $24.00Juniper Pharmaceuticals (JNP) Price Target Raised to $24.00
www.americanbankingnews.com - March 9 at 8:32 PM
Juniper Pharmaceuticals (JNP) Announces  Earnings Results, Beats Estimates By $0.22 EPSJuniper Pharmaceuticals (JNP) Announces Earnings Results, Beats Estimates By $0.22 EPS
www.americanbankingnews.com - March 9 at 4:15 PM
Juniper Pharmaceuticals, Inc. to Host Earnings CallJuniper Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - March 8 at 9:34 AM
Juniper Pharmaceuticals Reports Full-Year 2017 Financial and Operating ResultsJuniper Pharmaceuticals Reports Full-Year 2017 Financial and Operating Results
finance.yahoo.com - March 8 at 9:34 AM
Juniper Pharmaceuticals to Report Fourth Quarter and Year-End 2017 Results on March 8, 2018Juniper Pharmaceuticals to Report Fourth Quarter and Year-End 2017 Results on March 8, 2018
finance.yahoo.com - March 2 at 8:45 AM
Juniper Pharmaceuticals (JNP) & Histogenics (HSGX) Financial ComparisonJuniper Pharmaceuticals (JNP) & Histogenics (HSGX) Financial Comparison
www.americanbankingnews.com - March 2 at 1:16 AM
 Brokerages Expect Juniper Pharmaceuticals Inc (JNP) Will Announce Quarterly Sales of $13.20 Million Brokerages Expect Juniper Pharmaceuticals Inc (JNP) Will Announce Quarterly Sales of $13.20 Million
www.americanbankingnews.com - February 19 at 2:22 AM
 Brokerages Expect Juniper Pharmaceuticals Inc (JNP) Will Post Earnings of -$0.16 Per Share Brokerages Expect Juniper Pharmaceuticals Inc (JNP) Will Post Earnings of -$0.16 Per Share
www.americanbankingnews.com - February 17 at 11:16 PM
Juniper Pharmaceuticals Inc (JNP) Expected to Announce Earnings of -$0.16 Per ShareJuniper Pharmaceuticals Inc (JNP) Expected to Announce Earnings of -$0.16 Per Share
www.americanbankingnews.com - February 1 at 1:12 AM
Juniper Pharma (JNP) to Explore Strategic AlternativesJuniper Pharma (JNP) to Explore Strategic Alternatives
www.streetinsider.com - January 31 at 3:28 PM
Juniper Pharmaceuticals to Explore Strategic AlternativesJuniper Pharmaceuticals to Explore Strategic Alternatives
finance.yahoo.com - January 31 at 3:28 PM
$13.20 Million in Sales Expected for Juniper Pharmaceuticals Inc (JNP) This Quarter$13.20 Million in Sales Expected for Juniper Pharmaceuticals Inc (JNP) This Quarter
www.americanbankingnews.com - January 17 at 10:08 PM
-$0.16 EPS Expected for Juniper Pharmaceuticals Inc (JNP) This Quarter-$0.16 EPS Expected for Juniper Pharmaceuticals Inc (JNP) This Quarter
www.americanbankingnews.com - January 15 at 1:08 AM
Juniper Pharmaceuticals Announces 4.5-Year Extension through 2024 of CRINONE® Supply Agreement with Merck KGaA, Darmstadt, GermanyJuniper Pharmaceuticals Announces 4.5-Year Extension through 2024 of CRINONE® Supply Agreement with Merck KGaA, Darmstadt, Germany
finance.yahoo.com - January 8 at 9:25 AM
BRIEF-Juniper Pharmaceuticals Outlines Strategic Priorities For 2018 And Reports Recent Portfolio ProgressBRIEF-Juniper Pharmaceuticals Outlines Strategic Priorities For 2018 And Reports Recent Portfolio Progress
www.businessinsider.com - January 3 at 3:35 PM
Juniper Pharmaceuticals Outlines Strategic Priorities for 2018 and Reports Recent Portfolio ProgressJuniper Pharmaceuticals Outlines Strategic Priorities for 2018 and Reports Recent Portfolio Progress
finance.yahoo.com - January 2 at 8:51 PM
Juniper Pharmaceuticals (JNP) Coverage Initiated by Analysts at Roth CapitalJuniper Pharmaceuticals (JNP) Coverage Initiated by Analysts at Roth Capital
www.americanbankingnews.com - January 2 at 10:18 AM
Neuralstem (CUR) versus Juniper Pharmaceuticals (JNP) Critical ReviewNeuralstem (CUR) versus Juniper Pharmaceuticals (JNP) Critical Review
www.americanbankingnews.com - January 2 at 1:08 AM
Juniper Pharmaceuticals Inc (NASDAQ:JNP): What’s The Analyst Consensus Outlook?Juniper Pharmaceuticals Inc (NASDAQ:JNP): What’s The Analyst Consensus Outlook?
finance.yahoo.com - December 21 at 11:32 AM
ETFs with exposure to Juniper Pharmaceuticals, Inc. : December 19, 2017ETFs with exposure to Juniper Pharmaceuticals, Inc. : December 19, 2017
finance.yahoo.com - December 19 at 3:35 PM
Juniper Pharmaceuticals Inc (JNP) Receives Average Recommendation of "Hold" from BrokeragesJuniper Pharmaceuticals Inc (JNP) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - December 16 at 4:48 AM
Reviewing Juniper Pharmaceuticals (JNP) and Corium International (CORI)Reviewing Juniper Pharmaceuticals (JNP) and Corium International (CORI)
www.americanbankingnews.com - December 11 at 3:34 PM
Juniper Pharmaceuticals (JNP) Lowered to "Sell" at ValuEngineJuniper Pharmaceuticals (JNP) Lowered to "Sell" at ValuEngine
www.americanbankingnews.com - December 3 at 10:34 AM
ETFs with exposure to Juniper Pharmaceuticals, Inc. : December 1, 2017ETFs with exposure to Juniper Pharmaceuticals, Inc. : December 1, 2017
finance.yahoo.com - December 1 at 4:46 PM
Juniper Pharmaceuticals, Inc. (JNP) Receives Consensus Recommendation of "Buy" from BrokeragesJuniper Pharmaceuticals, Inc. (JNP) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - November 21 at 3:52 AM
ETFs with exposure to Juniper Pharmaceuticals, Inc. : November 20, 2017ETFs with exposure to Juniper Pharmaceuticals, Inc. : November 20, 2017
finance.yahoo.com - November 21 at 1:52 AM
Is Juniper Pharmaceuticals Inc’s (JNP) PE Ratio A Signal To Buy For Investors?Is Juniper Pharmaceuticals Inc’s (JNP) PE Ratio A Signal To Buy For Investors?
finance.yahoo.com - November 13 at 9:44 AM
ETFs with exposure to Juniper Pharmaceuticals, Inc. : November 8, 2017ETFs with exposure to Juniper Pharmaceuticals, Inc. : November 8, 2017
finance.yahoo.com - November 9 at 7:17 AM
Juniper Pharmaceuticals, Inc. :JNP-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017Juniper Pharmaceuticals, Inc. :JNP-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017
finance.yahoo.com - November 8 at 11:07 AM
Juniper Pharmaceuticals, Inc. (JNP) Scheduled to Post Earnings on MondayJuniper Pharmaceuticals, Inc. (JNP) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - November 6 at 12:26 PM
Juniper Pharmaceuticals posts 3Q lossJuniper Pharmaceuticals posts 3Q loss
www.cnbc.com - November 3 at 11:53 AM
Edited Transcript of JNP earnings conference call or presentation 2-Nov-17 8:30pm GMTEdited Transcript of JNP earnings conference call or presentation 2-Nov-17 8:30pm GMT
finance.yahoo.com - November 3 at 11:53 AM
Juniper Pharmaceuticals, Inc. (JNP) Receives Average Rating of "Buy" from AnalystsJuniper Pharmaceuticals, Inc. (JNP) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - October 27 at 3:50 AM
Juniper Pharmaceuticals to Report Third Quarter 2017 Results on November 2, 2017Juniper Pharmaceuticals to Report Third Quarter 2017 Results on November 2, 2017
finance.yahoo.com - October 27 at 1:24 AM
Juniper Pharmaceuticals Inc (JNP) Delivered A Better ROE Than The Industry, Here’s WhyJuniper Pharmaceuticals Inc (JNP) Delivered A Better ROE Than The Industry, Here’s Why
finance.yahoo.com - October 20 at 1:43 AM

SEC Filings

Columbia Laboratories (NASDAQ:JNP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Columbia Laboratories (NASDAQ:JNP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Columbia Laboratories (NASDAQ JNP) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.